PDIA3 and Parkinson disease: Since alterations in the activity of PDIs is observed in the brain of PD patients and animal models of the disease [24, 39, 40], we evaluated the possible effects of ERp57 overexpression in dopaminergic neuron survival using a pharmacological model of PD.